Jack Taunton and colleagues from the University of California, San Francisco have developed salicylaldehyde-based chemical probes that reversibly and covalently modify the catalytic lysine of protein kinases, with sustained occupancy in cells and animals.
DUBLIN – Anavo Therapeutics BV raised €20 million (US$24 million) in seed financing to fund the build-out of a platform that aims to drug the human phosphatome, or the ensemble of phosphatase enzymes that plays a crucial role in maintaining cells’ phosphorylation balance by removing phosphate groups from their target substrates.